This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Astrogenetix's MRSA Research Continues On Discovery's Last Mission

Stocks in this article: ASTC

AUSTIN, Texas, Feb. 24, 2011 (GLOBE NEWSWIRE) -- NASA astronauts onboard Space Shuttle Discovery's final mission to the International Space Station (ISS) will carry out the eleventh scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. The research on STS-133 will focus on changes that occur to methicillin-resistant Staphylococcus aureus (MRSA) in microgravity, which can be targeted to create new vaccines and therapeutics.

"The laboratory conditions present on the International Space Station do not exist anywhere else," said John Porter, Chief Executive Officer of Astrogenetix. "The use of this unique environment for research has created a breakthrough new development platform that is leading to amazing discoveries."

Current work is focused on the use of microgravity to identify targets for the development of therapeutics for MRSA. In the past decade, infection and mortality due to this organism has increased drastically, exceeding the death rate for HIV. In this country alone, MRSA is responsible for 100,000 cases of severe infections and 19,000 deaths annually. Previous spaceflight results have shown successful identification of genes in MRSA associated with virulence of this organism in our unique model system.  The research on STS-133 seeks to validate previously identified gene targets for MRSA virulence, as well as investigating an additional gene target for this devastating microbe.

"By understanding the specific biological changes that cause the development of more virulent bacteria we can develop better therapeutics and vaccines," said Dr. Jeanne Becker, Chief Science Officer for Astrogenetix. "We can now begin to target these changes specifically caused by microgravity and better control diseases."

In 2005 ISS was designated a National Lab opening up the facility to private sector researchers. Astrogenetix was created as a subsidiary of Astrotech Corporation (Nasdaq:ASTC) in 2008 to utilize the unique environment of microgravity found on the ISS to develop and commercialize biotechnology products. Over the last two years, Astrogenetix has carried out ten research missions utilizing microgravity, leading to the identification of a gene target for Salmonella enterica and its application towards development of an attenuated vaccine is under investigation. BioServe Space Technologies is providing the hardware, integration and operations support for the research, which is being performed in conjunction with researchers at the Durham VA Medical Center in North Carolina. 

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.55 +7.90 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs